Earlier this summer the FDA asked Moderna for more efficacy data on its flu vaccine before it could review an mRNA-based ...

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

The label for Moderna's RSV vaccine mResvia has been expanded to include adults aged 18 and over in the US, but will that lead to an uptick in sales?